A5001308517- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Multiple and Secondary Primary Cancers
- Epigenetics and DNA Methylation
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Cancer Research and Treatments
- Radiopharmaceutical Chemistry and Applications
- Immune cells in cancer
- Cancer Genomics and Diagnostics
- Urological Disorders and Treatments
- Fibroblast Growth Factor Research
- Ferroptosis and cancer prognosis
- Cancer Treatment and Pharmacology
- Cancer Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Esophageal Cancer Research and Treatment
- Metastasis and carcinoma case studies
- HER2/EGFR in Cancer Research
- Cancer, Lipids, and Metabolism
- Peptidase Inhibition and Analysis
- Prostate Cancer Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Renal and related cancers
Johns Hopkins University
2016-2025
Johns Hopkins Medicine
2016-2025
Sidney Kimmel Comprehensive Cancer Center
2016-2025
Bladder Cancer Advocacy Network
2018-2024
University Hospital Regensburg
2024
Johns Hopkins Hospital
2016-2024
University of Baltimore
2015-2023
Indiana University – Purdue University Indianapolis
2008-2022
Indiana University Health
2007-2022
New York University
2021
Androgen-deprivation therapy (ADT) has been the backbone of treatment for metastatic prostate cancer since 1940s. We assessed whether concomitant with ADT plus docetaxel would result in longer overall survival than that alone.
Purpose Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostate cancer. Herein, we present outcomes CHAARTED (Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) trial more mature follow-up and focus on tumor volume. Patients Methods In this phase III study, 790 cancer were equally randomly assigned receive either ADT combination docetaxel 75...
The data reported herein were accepted for assessment by the US Food and Drug Administration Biologics License Application under priority review to establish clinical benefit of durvalumab as second-line therapy locally advanced or metastatic urothelial carcinoma (UC), resulting in its recent approval.To report a planned update safety efficacy patients with advanced/metastatic UC.This is an ongoing phase 1/2 open-label study 191 adult histologically cytologically confirmed UC whose disease...
Locally advanced or metastatic urothelial carcinoma is an incurable disease with limited treatment options, especially for patients who were previously treated platinum and anti-programmed death 1 ligand (PD-1/L1) therapy. Enfortumab vedotin antibody-drug conjugate that targets Nectin-4, which highly expressed in carcinoma.EV-201 a global, phase II, single-arm study of enfortumab 1.25 mg/kg (intravenously on days 1, 8, 15 every 28-day cycle) locally chemotherapy anti-PD-1/L1 The primary end...
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy muscle-invasive urothelial bladder cancer, as substantial revisions were made 2017 updates, such new recommendations nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of addresses additional aspects management including non-muscle-invasive cancer nonurothelial histologies, well staging, evaluation, follow-up.
PURPOSE The phase II single-arm KEYNOTE-052 study evaluated the efficacy and safety of first-line pembrolizumab for patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma (UC). PATIENTS AND METHODS Three hundred seventy received 200 mg intravenously every 3 weeks up to 24 months. Positive tumor programmed death ligand 1 (PD-L1) expression was defined as combined positive score (CPS) ≥ 10. Response assessed by independent central review 9 per RECIST v1.1....
The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These Insights discuss important updates to 2018 version guidelines, including implications 8th edition AJCC Staging Manual on treatment muscle-invasive cancer incorporating newly approved immune checkpoint inhibitor therapies into options locally advanced or metastatic disease.
Novel approaches are needed for patients with metastatic urothelial cancer (UC). This trial assessed the efficacy and toxicity of bevacizumab in combination cisplatin gemcitabine (CGB) as first-line treatment UC.Chemotherapy-naive or unresectable UC received 70 mg/m(2) on day 1, 1,000 to 1,250 days 1 8, 15 mg/kg every 21 days.Forty-three performance status 0 (n = 26) 17) median age 66 years were evaluable response. Grade 3 4 hematologic included neutropenia (35%), thrombocytopenia (12%),...
Vandetanib is an oral once-daily tyrosine kinase inhibitor with activity against vascular endothelial growth factor receptor 2 and epidermal receptor. in combination docetaxel was assessed patients advanced urothelial cancer (UC) who progressed on prior platinum-based chemotherapy.The primary objective to determine whether vandetanib 100 mg plus 75 mg/m(2) intravenously every 21 days prolonged progression-free survival (PFS) versus placebo docetaxel. The study designed detect a 60%...
LBA2 Background: Docetaxel (D) improves OS of men with mPrCa who have progressed on androgen deprivation therapy (ADT). We aimed to assess the benefit upfront chemohormonal for metastatic PrCa. Methods: 1:1 randomization ADT alone or + D dosed 75mg/m2 every 3 weeks 6 cycles within 4 month (mos) starting ADT. Stratification factors: high volume (HV) vs. low (LV) disease (HV: visceral metastases and/or more bone metastases); anti-androgen use beyond 30 days; Age ≥70 < 70 years; ECOG PS 0-1...
Introduction: Randomized controlled trials of platinum-based neoadjuvant chemotherapy (NAC) for bladder cancer have shown that patients who achieve a pathologic response to NAC exhibit 5 y survival rates approximately 80–90% while resistant (NR) cases 30–40%. These findings highlight the need predict will benefit from conventional and plausible alternatives. Methods: The pre-treatment biopsy tissues cohort 41 with muscle invasive were treated incorporated in tissue microarray...
These NCCN Guidelines Insights discuss the major recent updates to for Bladder Cancer based on review of evidence in conjunction with expert opinion panel. Recent include (1) refining recommendation intravesical bacillus Calmette-Guérin, (2) strengthening recommendations perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy locally advanced or metastatic disease. further factors that affect integration these clinical practice.
Platinum-based chemotherapy for first-line treatment of metastatic urothelial cancer is typically administered a fixed duration followed by observation until progression. "Switch maintenance" therapy with PD-1 blockade at the time cessation may be attractive mechanistic and pragmatic reasons.Patients achieving least stable disease on platinum-based were enrolled. Patients randomly assigned double-blind 1:1 to switch maintenance pembrolizumab 200 mg intravenously once every 3 weeks versus...
Data supporting neoadjuvant chemotherapy of high grade upper tract urothelial carcinoma are scant. In this multi-institution, prospective, phase II trial we investigated pathological complete responses after carcinoma.Patients with in whom nephroureterectomy was planned were assigned to 4 cycles accelerated methotrexate, vinblastine, doxorubicin and cisplatin those baseline creatinine clearance greater than 50 ml per minute or gemcitabine carboplatin 30 less. The study primary end point a...
The antibody-drug conjugate enfortumab-vedotin acts by targeting nectin-4, a protein that is nearly ubiquitously expressed in conventional urothelial cancer. However, expression of nectin-4 morphologic variants carcinoma and nonurothelial histotypes was unknown. Immunohistochemistry for using performed on 169 patients including 83 with nonmuscle invasive bladder cancer 86 muscle Staining scored intensity (0 to 3) extent (% positive cells) the histological score system, where >15 considered...